Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13)
Year of publication
Document Type
- Journal article (13)
Language
- English (13)
Keywords
- prostate cancer (5)
- RCC (2)
- biomarker (2)
- biomarkers (2)
- high-risk prostate cancer (2)
- prognosis (2)
- Biomarker (1)
- Cancer Cell (1)
- CpG island hypermethylation (1)
- GSTP1 (1)
Institute
- Urologische Klinik und Poliklinik (13)
- Theodor-Boveri-Institut für Biowissenschaften (7)
- Pathologisches Institut (3)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Klinische Biochemie und Pathobiochemie (1)
- Medizinische Klinik und Poliklinik I (1)
Sonstige beteiligte Institutionen
Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n=86 ) or no adjuvant ADT (group 2, n=86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5–10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.